The Luo Lab studies hypoxia-inducible factor (HIF)-dependent and independent epigenetic and metabolic alterations in development and tumorigenesis with a goal of identifying vulnerability to treat cancers. We utilize in vitro and in vivo models including genetic mouse models, patient-derived xenograft models, and organoid models in our studies. Currently, our research is supported by grants from NCI, CPRIT, and ACS.

We are interested in the role of post-translational modifications in HIF transcriptional activity (Bao L, et al., Nucleic Acids Res 2018; Luo W et al., J Biol Chem 2010).
We are interested in studying interplay between HIF and epigenetic regulators as well as epigenetic regulation of development and cancer (Wang Y, et al., Cancer Res 2020; Chen Y, et al., JCI 2018).
We are interested in identification of HIF-dependent metabolic reprogramming in human cancers and possible metabolic therapy (Zhang B, Chen Y, et al. Cell Mol Life Sci 2021; Peng H et al. Oncogene 2020; Zhang B, Chen Y, et al., Cells 2022).
We are interested in epigenetic and metabolic regulation of development and tumorigenesis and their therapies (Luo M, et al., Sci Adv 2022; Zhang B, Peng H, et al., Cancer Res 2022; Wang Y et al., Cancer Res 2021).